

Navin Fluorine International Limited

Result Update Presentation

Q1 FY18

Safe Harbor



This presentation and the accompanying slides (the "Presentation"), which have been prepared by Navin Fluorine International Limited (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.


This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Standalone Financial Highlights









Quarter 1 Standalone Profitability Statement [as per Ind AS]



Particulars (Rs. Crs.)	Q1 FY18	Q1 FY17	Change %
Revenue from Operations	238	174	36%
Raw Material	94	65	
Excise Duty	13	12	
Employee Expenses	21	18	
Other Expenses	51	40	
EBITDA	59	40	47%
EBITDA Margin	25.0%	23.1%	185 bps
Interest Expenses	0	0	
Depreciation	10	6	
Operating PBT	49	34	43%
Operating PBT Margin	20.5%	19.7%	89 bps
Other Income	26	21	
PBT	75	55	37%
Tax	26	11	
Profit After Tax	49	44	13%
Other Comprehensive Income			
Items that will not be reclassified to Profit & Loss (net of tax)	-0.8	-0.4	
Total Comprehensive income for the Period	48	43	
Cash Profit*	60	50	20%

^{*} Cash Profit = Profit After Tax for the Period + Depreciation




Business Units Performance

^ as per Ind AS financials



30

Q1 FY18^



PADMANABH MAFATLAL GROUP


Domestic

90%

Business Units Performance




Exports 100%



Revenue Mix: Business Unit Wise






^{*} Standalone Results



[^] as per Ind AS financials

Annual Financial Performance#






Increasing demands for cooling solutions & as feedstock for Pharmaceutical industry to drive long term growth

Traction in Key product portfolios & Customer segments

17%




31%

20%

Revenue Break-up


FY17



Ramp up in successful delivery across a range of orders from **Innovator pharmaceutical Majors** through effective leveraging of the cGMP facility at Dewas & integration with M.O.L.

Continuing Focus on niche offerings & key customer interface, backed up by strong product pipeline

33%






^{*} CRAMS business generating revenue since FY13 # as per I GAAP financials

Strategy Begins to Yield Results








^{*} Standalone Results

^{# -} Calculated based on I GAAP Financials

Consistent Dividend Performance





Robust Dividend Payout

- ✓ Continuous Dividend since last 10 years
- ✓ Special Dividend of Rs. 60.00 per share in FY12
- ✓ Declared Interim Dividend of Rs. 11.00 per share and a Special Dividend of Rs.7.50 per share on 24th Oct. 2016
- ✓ Final Dividend of Rs. 13.00 per share in FY17

Total Dividend of Rs. 31.50 per share in FY17 including the Special Dividend of Rs. 7.50 per share, Interim Dividend of Rs. 11.00 per share and Final Dividend of Rs. 13.00 per share







Particulars (Rs. Crs.)	FY17	FY16	Change %
Revenue	701	636	10%
Raw Material	286	292	
Employee Expenses	77	66	
Other Expenses	189	162	
Operating EBITDA	150	116	29%
Operating EBITDA Margin	21.4%	18.2%	320 bps
Interest Expenses	0	3	
Depreciation	28	21	
Operating PBT	121	92	32%
Operating PBT Margin	17.3%	14.5%	280 bps
Other Income	30	25	
PBT before exceptional item	151	117	
Exceptional items	27	0	
PBT after exceptional items	178	117	
Tax	44	30	
Profit After Tax	134	86	56%
Adjusted PAT*	107	86	24%
Adjusted PAT* Margin	15.3%	13.5%	180 bps
Cash Profit**	135	107	26 %
Cash Profit** Margin	19.3%	16.8%	250 bps

^{*} Adjusted PAT = PAT - Exceptional Items



^{**} Cash Profit = Adjusted PAT + Depreciation

Standalone Balance Sheet [as per I GAAP]



Equity and Liabilities (Rs. Crs.)	Mar'17	Mar'16
Shareholder's Fund	748	634
Share capital	10	10
Reserves & Surplus	738	624
Non-current liabilities	69	63
Long term borrowings	0	0
Deferred Tax Liabilities (net)	42	36
Other non-current liabilities	19	21
Long Term Provisions	7	6
Current liabilities	250	152
Short term borrowings	0	30
Trade Payables	92	92
Other current liabilities	143	12
Short Term Provision	15	18
Total Equity and Liabilities	1,067	849

Assets (Rs. Crs.)	Mar'17	Mar'16
Non-current assets	690	542
Fixed assets	428	282
Tangible Assets	411	267
Intangible Assets	0	1
Capital Work in Progress	17	14
Non-current Investments	212	213
Long-term loans and advances	50	48
Current assets	377	306
Current Investments	80	53
Inventories	99	63
Trade receivables	129	139
Cash and bank balances	30	15
Short Term Loans & Advances	37	34
Other current assets	2	3
Total Assets	1,067	849







Particulars (Rs. Crs.)	FY17	FY16	Change %
Revenue	748	680	10%
Raw Material	303	311	
Employee Expenses	92	81	
Other Expenses	195	171	
Operating EBITDA	158	117	35%
Operating EBITDA Margin	21.1%	17.2%	390 bps
Interest Expenses	2	4	
Depreciation	30	22	
Operating PBT	126	91	38%
Operating PBT Margin	16.8%	13.4%	340 bps
Other Income	31	24	
PBT before exceptional item	157	116	
Exceptional items	27	0	
PBT after exceptional items	184	116	
Тах	46	32	
Profit After Tax	138	84	64%
Adjusted PAT*	111	84	32%
Adjusted PAT* Margin	14.8%	12.4%	240 bps
Cook Bushis**	141	100	220/
Cash Profit **	141	106	33%
Cash Profit ** Margin	18.9%	15.6%	330 bps

^{*} Adjusted PAT = PAT - Exceptional Items



^{**} Cash Profit = Adjusted PAT + Depreciation


Consolidated Balance Sheet [as per I GAAP]



Equity and Liabilities (Rs. Crs.)	Mar'17	Mar'16
Shareholder's Fund	765	645
Share capital	10	10
Reserves & Surplus	755	636
Minority Interest	0	o
Non-current liabilities	123	113
Long term borrowings	51	48
Deferred Tax Liabilities (net)	43	37
Other non-current liabilities	21	23
Long Term Provisions	7	6
Current liabilities	220	196
Short term borrowings	19	34
Trade Payables	94	96
Other current liabilities	93	49
Short Term Provision	15	18
Total Equity and Liabilities	1,107	955

Assets (Rs. Crs.)	Mar'17	Mar'16
Non-current assets	689	608
Fixed assets	460	307
Tangible Assets	428	286
Intangible Assets	0	1
Capital Work in Progress	31	20
Goodwill on Consolidation	88	88
Non-current Investments	108	117
Long-term loans and advances	33	96
Current assets	419	347
Current Investments	80	53
Inventories	113	76
Trade receivables	136	151
Cash and bank balances	48	29
Short Term Loans & Advances	38	34
Other current assets	4	4
Total Assets	1,107	955








Business Overview




Overview





Business Units (BU) - Standalone





Clients across the Globe





Key Strengths



Fluorination Capabilities

- ✓ Pioneered Manufacturing of Refrigerant Gases in India
- ✓ Over 45 years of experience in handling Fluorine
- Extensive expertise focusing on specialty fluorine chemistry

Manufacturing

- Chemical Complex at Surat spread over 135 acres, houses Refrigerant, Inorganic Fluorides & Specialty Chemicals Plants
- ✓ cGMP Compliant Pilot plant for CRAMS in Dewas
- ✓ cGMP Compliant Manufacturing plant for CRAMS fully operational.

In-house R&D

- ✓ State-of-the-art R&D centre Navin Research Innovation Centre at Surat
- ✓ DSIR approved R&D Centre
- ✓ Supports in product addition & process efficiency in all business units
- R&D strength augmented by Manchester Organics Acquisition

Raw Material Sourcing

- ✓ Backward integration for Raw material through 25% JV partner in the only Fluorspar beneficiation company in India
- ✓ Diversified sourcing of Fluorspar away from China



Growth driven by Every Business Unit



CRAMS

- ✓ Business progression from Contract research to contract manufacturing
- ✓ Manufacturing facility commercially operational

Specialty Chemicals

- ✓ Introduction of new high value added molecules in portfolio
- ✓ Entry into newer geographies

Inorganic Fluorides

- ✓ Introduction of new molecules in portfolio
- ✓ Entry into newer geographies

Refrigerant Gases

- ✓ Strong demand for air conditioning and refrigeration equipment
- ✓ Increasing usage as feedstock in pharma





For further information, please contact:

Company :	Investor Relations Advisors :
Navin Fluorine International Ltd.	Strategic Growth Advisors Pvt. Ltd.
CIN: L24110MH1998PLC115499	CIN: U74140MH2010PTC204285
Mr. Sitendu Nagchaudhuri Chief Financial Officer sitendu.nagchaudhuri@nfil.in	Ms. Payal Dave / Mr Jigar Kavaiya 98199 16314 / 99206 02034 payal.dave@sgapl.net / jigar.kavaiya@sgapl.net
www.nfil.in	www.sgapl.net

